# Perceive Biotherapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/perceive-biotherapeutics

- Industry: Healthcare
- Headquarters: South San Francisco, US
- Website: www.perceivebio.com
- Total disclosed funding: $55M
- Latest round: Series B (Feb 18, 2025)
- Investors on record: 6

## About

Based in California, US, and founded in 2020, Perceive Biotherapeutics, Inc. operates as a healthcare platform that engages in developing a therapeutic technology that could help patients with eye diseases. In February 2025, Perceive Biotherapeutics, Inc. raised USD 15 million in series A funding from new investor GV, with participation from returning investors Deerfield Management, Johnson & Johnson Innovation, Braidwell, Retinal Degeneration Fund, Catalio Capital Management. As of January 2023, K. Angela Macfarlane, JD is the Chief Executive Officer (CEO) of the company. Perceive Biotherapeutics is focused on the discovery and development of transformative gene therapies and other therapeutics for ocular diseases with high unmet needs that develop new eye care therapeutics to address major unmet patient needs. The company develops a channel of assets with differentiated targets using multiple therapeutic modalities, assisting medical professionals in preventing the leading causes of unpreventable blindness. The company will use the February 2025 funding to advance the clinical development of its lead glaucoma program and further its research into neuroprotective therapies for other undisclosed disease areas.

## Funding rounds

- Series B, Feb 18, 2025, $15M — Johnson & Johnson Innovation, GV, Deerfield Management, Catalio Capital Management, Braidwell, Retinal Degeneration Fund
- Series B, Dec 29, 2022, $40M — Johnson & Johnson Innovation, Deerfield Management, Catalio Capital Management, Braidwell, Retinal Degeneration Fund

## Investors

- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series B
- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series B
- Catalio Capital Management (https://capitalatlas.ai/funds/catalio-capital-management) — Series B
- Braidwell (https://capitalatlas.ai/funds/braidwell) — Series B
- Retinal Degeneration Fund (https://capitalatlas.ai/funds/retinal-degeneration-fund) — Series B
- GV (https://capitalatlas.ai/funds/gv) — Series B